Blepharophimosis
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Blepharophimosis

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Blepharophimosis Local Doctors?
Elite in Blepharophimosis
Elite in Blepharophimosis
Gent, VLG, BE 

Elfride De Baere practices in Gent, Belgium. De Baere is rated as an Elite expert by MediFind in the treatment of Blepharophimosis. Their top areas of expertise are Blepharophimosis, Leber Congenital Amaurosis, Retinopathy Pigmentary Mental Retardation, Vitrectomy, and Cataract Removal.

Elite in Blepharophimosis
Elite in Blepharophimosis
Gent, VLG, BE 

Hannah Verdin practices in Gent, Belgium. Ms. Verdin is rated as an Elite expert by MediFind in the treatment of Blepharophimosis. Her top areas of expertise are Blepharophimosis, Congenital Microcoria, Retinopathy Pigmentary Mental Retardation, Vitrectomy, and Cataract Removal.

 
 
 
 
Learn about our expert tiers
Learn More
Nara L. De Macena Sobreira
Distinguished in Blepharophimosis
Medical Genetics | Pediatrics
Distinguished in Blepharophimosis
Medical Genetics | Pediatrics

Rubenstein Child Health Building

Baltimore, MD 
Languages Spoken:
English, Portuguese

Dr. Nara Lygia De Macena Sobreira is an assistant professor at the McKusick-Nathans Department of Genetic Medicine at Johns Hopkins University School of Medicine. Her area of expertise is rare Mendelian phenotypes, analysis of next-generation sequencing, and functional testing of candidate causative variants. She earned her M.D. at the University of Pernambuco in Brazil. She finished her Ph.D. in Human Genetics at Johns Hopkins followed by a one-year postdoc also at Johns Hopkins School of Medicine. During her Ph.D., she worked with Dr. David Valle using next-generation sequencing to elucidate the molecular basis of rare Mendelian phenotypes and in 2010 she discovered PTPN11 as the gene responsible for metachondromatosis by using whole-genome sequencing. She completed residencies in clinical genetics at both Universidade Federal de Sao Paulo and Johns Hopkins. Her main clinical and research focus is on identifying the genetic bases of rare phenotypes, mainly, phenotypes associated with cartilage tumors and vascular anomalies (including Ollier disease and Maffucci syndrome), and on understanding the physiopathology of these phenotypes to identify pharmacological strategies to treat them. She has worked extensively on developing strategies to better analyze the variants identified by next-generation sequencing and on novel strategies for data sharing. She participated on the development of PhenoDB, a phenotypic and genomic database, and created PhenoDB Variant Analysis Tool used worldwide. She is also one of the creators of GeneMatcher, VariantMatcher, and one of the co-founders of the Matchmaker Exchange, all intended to share next-generation sequencing data. She has also worked extensively on functional studies that evaluate the possible pathogenic effects of the candidate causative variants. Recent News Articles and Media Coverage Living the Hopkins Mission Honorees, Johns Hopkins Medicine Successes in Characterizing Genes through GeneMatcher with Nara L. M. Sobreira, MD, PhD, Ambry Genetics (April 30, 2018) Enfermedades raras: el desafio es encontrar otros pacientes que tienen el mismo mal, Lun (26 de septiembre de 2019) 2021 Science Writers' Boot Camp, Johns Hopkins Medicine (June 7, 2021) Making the Perfect Match, Johns Hopkins Medicine (February 1, 2020). Dr. De Macena Sobreira is rated as a Distinguished provider by MediFind in the treatment of Blepharophimosis. Her top areas of expertise are Spondyloepimetaphyseal Dysplasia Strudwick Type, Greenberg Dysplasia, Blepharophimosis, and Early Infantile Epileptic Encephalopathy.

What are the latest Blepharophimosis Clinical Trials?
A Randomised, Double-Masked, Placebo-Controlled Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops) Used Twice Daily (BID) in the Treatment of Acquired Blepharoptosis

Summary: A Randomised, Double-Masked, Placebo-Controlled Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops) used twice daily (BID) in the Treatment of Acquired Blepharoptosis

Match to trials
Find the right clinical trials for you in under a minute
Get started